Lifesci Capital Decreases Earnings Estimates for Immunovant

Immunovant, Inc. (NASDAQ:IMVT) – Analysts at Lifesci Capital cut their FY2025 EPS estimates for shares of Immunovant in a research report issued on Sunday, February 23rd. Lifesci Capital analyst S. Slutsky now forecasts that the company will post earnings per share of ($2.64) for the year, down from their previous forecast of ($2.36). The consensus estimate for Immunovant’s current full-year earnings is ($2.69) per share. Lifesci Capital also issued estimates for Immunovant’s Q4 2025 earnings at ($0.56) EPS.

Several other equities research analysts have also recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $51.00 target price on shares of Immunovant in a report on Friday, February 7th. Wells Fargo & Company lowered their price objective on shares of Immunovant from $47.00 to $45.00 and set an “overweight” rating for the company in a research note on Thursday, December 19th. Bank of America cut their target price on shares of Immunovant from $48.00 to $45.00 and set a “buy” rating on the stock in a research report on Wednesday, January 15th. Guggenheim lowered their price target on shares of Immunovant from $46.00 to $44.00 and set a “buy” rating for the company in a research report on Monday, February 10th. Finally, Cantor Fitzgerald raised shares of Immunovant to a “strong-buy” rating in a report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Immunovant has a consensus rating of “Buy” and an average target price of $45.90.

Immunovant Stock Performance

Shares of NASDAQ IMVT opened at $20.08 on Wednesday. Immunovant has a 52-week low of $19.07 and a 52-week high of $39.55. The firm has a market capitalization of $3.41 billion, a price-to-earnings ratio of -7.66 and a beta of 0.65. The stock has a 50 day moving average price of $22.70 and a 200 day moving average price of $27.05.

Immunovant (NASDAQ:IMVT) last issued its earnings results on Monday, February 10th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.08).

Insider Transactions at Immunovant

In related news, CEO Peter Salzmann sold 5,105 shares of the business’s stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $24.10, for a total transaction of $123,030.50. Following the transaction, the chief executive officer now directly owns 972,992 shares in the company, valued at $23,449,107.20. The trade was a 0.52 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider William L. Macias sold 2,383 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $23.83, for a total value of $56,786.89. Following the completion of the sale, the insider now directly owns 359,408 shares of the company’s stock, valued at approximately $8,564,692.64. This represents a 0.66 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 27,510 shares of company stock valued at $656,886. Corporate insiders own 5.90% of the company’s stock.

Institutional Trading of Immunovant

Several large investors have recently bought and sold shares of the stock. KBC Group NV lifted its stake in shares of Immunovant by 46.2% during the third quarter. KBC Group NV now owns 1,936 shares of the company’s stock worth $55,000 after buying an additional 612 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Immunovant in the 4th quarter valued at $76,000. Assetmark Inc. lifted its position in Immunovant by 73.8% during the 3rd quarter. Assetmark Inc. now owns 2,891 shares of the company’s stock worth $82,000 after acquiring an additional 1,228 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in Immunovant by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,294 shares of the company’s stock valued at $148,000 after purchasing an additional 934 shares during the last quarter. Finally, Ameriprise Financial Inc. purchased a new stake in Immunovant during the 4th quarter valued at about $221,000. Hedge funds and other institutional investors own 47.08% of the company’s stock.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.